Adds to existing law to provide that ivermectin may be sold or purchased without a prescription or consultation with a health care professional.
Summary
Senate Bill 1211 would amend Idaho law to allow ivermectin suitable for human use to be sold and purchased in the state as an over-the-counter medication. The bill states that ivermectin may be obtained without a prescription and without consultation with a health care professional, notwithstanding any contrary law. It also includes an emergency clause, meaning it would take effect immediately upon passage and approval.
The measure is narrow in scope and does not create a broader regulatory framework for ivermectin; instead, it directly removes any state-law barrier to nonprescription access for the drug. By defining ivermectin as eligible for over-the-counter sale and purchase, the bill would affect pharmacies, retailers, consumers, and health care providers by eliminating the prescription requirement under Idaho law.
Impact
If enacted, the bill would amend Title 37 of the Idaho Code by adding a new section, 37-135, governing ivermectin access. It would preempt any conflicting state law or rule that requires a prescription or medical consultation for ivermectin suitable for human use, effectively changing the drug’s status in Idaho from prescription-only to over-the-counter for state-law purposes. The practical effect would be to expand consumer access and reduce the role of prescribers and pharmacists in dispensing decisions for this medication.
Sentiment
The voting history suggests the bill had substantial support overall, with passage in the Senate by a 25-9 vote and in the House by a 66-1 vote. That margin indicates broad legislative approval, especially in the House, and little recorded opposition in the available materials. No committee transcripts were provided, so there is no additional recorded discussion to indicate divided views beyond the floor votes.
Contention
The main point of contention is the removal of the prescription and health-care-consultation requirement for ivermectin. Supporters appear to favor making the medication more readily available to consumers, while opponents likely object to bypassing medical oversight for a drug that is ordinarily regulated through prescription channels. Because no committee debate transcript is available, the specific arguments on safety, appropriate use, or regulatory authority are not documented in the provided record.